Clinical Edge Journal Scan

Meta-analysis demonstrates increased risk for non-breast second primary cancers in BC survivors


 

Key clinical point: The risk for non-breast second primary cancer (SPC) at many sites was significantly elevated in female breast cancer (BC) survivors, particularly those who were first diagnosed with BC before the age of 50 years.

Major finding : The summary standardized incidence ratio (SIR) for non-breast SPC was estimated to be 1.24 (95% CI 1.14-1.36), with the risk being significantly higher among patients diagnosed with BC before vs after the age of 50 years (SIR 1.59 vs 1.13; P < .001). The risk for non-breast SPC was the highest at the thyroid (SIR 1.89; 95% CI 1.49-2.38), followed by corpus uteri, ovary, kidney, esophagus, skin (melanoma), blood (leukemia), lung, stomach, and bladder.

Study details: Findings are from a meta-analysis of one prospective and 27 retrospective studies.

Disclosures: This study was funded by the CRUK Catalyst Award CanGene-CanVar, UK. The authors declared no conflicts of interest.

Source: Allen I et al. Risks of second non-breast primaries following breast cancer in women: A systematic review and meta-analysis. Breast Cancer Res. 2023;25(1):18 (Feb 10). Doi: 10.1186/s13058-023-01610-x

Recommended Reading

Surgery for early breast cancer can worsen frailty in older women
MDedge Hematology and Oncology
Omitting radiotherapy increases local recurrence risk without affecting other survival outcomesin HR+ early BC
MDedge Hematology and Oncology
Epirubicin+paclitaxel noninferior to epirubicin+cyclophosphamide followed by paclitaxel in HR+/ERBB2- BC
MDedge Hematology and Oncology
Minimal prognostic differences exist between ERBB2-low and ERBB2-negative BC2- BC
MDedge Hematology and Oncology
Anthracycline+taxane regimens benefit older TNBC patients with higher lymph node involvement
MDedge Hematology and Oncology
pCR: An excellent prognostic marker in HR+/HER2+ early BC treated with de-escalated chemotherapy-free anti-HER2 therapy
MDedge Hematology and Oncology
Hysterectomy combined with hormone therapy increases BC risk
MDedge Hematology and Oncology
Neoadjuvant pegylated liposomal doxorubicin-based treatment shows potential in early-stage BC
MDedge Hematology and Oncology
HR+/HER2− metastatic BC: Greater survival benefit observed with ET+CDK4/6 inhibitor vs ET
MDedge Hematology and Oncology
ER− primary BC associated with higher risk for secondary BCs in initial years
MDedge Hematology and Oncology